首页 | 本学科首页   官方微博 | 高级检索  
   检索      

研究报告:蚓激酶同工酶降解乙型肝炎抗原并保护肝功能
引用本文:周园,牟丽娴,范士超,王秀梅,曹潇,王学清,张奉学,赵静,魏艳,赫荣乔.研究报告:蚓激酶同工酶降解乙型肝炎抗原并保护肝功能[J].生物化学与生物物理进展,2022,49(1):202-218.
作者姓名:周园  牟丽娴  范士超  王秀梅  曹潇  王学清  张奉学  赵静  魏艳  赫荣乔
作者单位:2) 中国科学院生物物理研究所,北京 100101,1) 西南医科大学基础医学院,泸州 646000,2) 中国科学院生物物理研究所,北京 100101,2) 中国科学院生物物理研究所,北京 100101,1) 西南医科大学基础医学院,泸州 646000,3) 北京大学药学院,分子药剂学与新释药系统北京市重点实验室,北京 100191,4) 广州中医药大学基础医学院,广州 510099,2) 中国科学院生物物理研究所,北京 100101,2) 中国科学院生物物理研究所,北京 100101,1) 西南医科大学基础医学院,泸州 646000;2) 中国科学院生物物理研究所,北京 100101
基金项目:国家自然科学(31470036)基金资助项目。
摘    要:目的蚓激酶同工酶(LKIs)作为肠溶胶囊的有效成分,用于治疗血栓性疾病已有30多年历史。近年来,LKIs在其他危重疾病中的研究时有报道。本文关注LKIs在乙型肝炎方面的作用。方法乙型肝炎表面抗原(HBs Ag)、核心抗原(HBcAg)和e抗原(HBeAg)分别与不同浓度LKIs孵育,观察这些蛋白质的降解和估计肽链的切割位点。Hep G2.2.15细胞与LKIs孵育,采用酶联免疫吸附测定(ELISA)和蛋白质印迹(Western blotting)检测细胞分泌的HBsAg和HbeAg。LKIs灌胃Balb/c小鼠30天,采用ELISA和Western blotting检测其血清HBsAg和HBeAg,免疫组化染色检测肝组织中的HBcAg。采用苏木精-伊红染色分析乙肝病毒转基因小鼠肝组织的损害,并通过ELISA定量分析血清谷草转氨酶(GOT)和谷丙转氨酶(GPT)。腹腔注射后,取大鼠血清和肝组织,测定其中的LKIs含量,从而观察LKIs的吸收。采用LKIs给龙岩麻鸭灌胃30天,通过PCR检测其血清HBV DNA。结果蚓激酶肠溶胶囊的有效成分是含有6种LKIs的复方蛋白酶药物,可以降解HBV...

关 键 词:HBeAg  HBcAg  HBsAg  蚓激酶同工酶  乙肝病毒  同工酶
收稿时间:2022/1/5 0:00:00
修稿时间:2022/1/5 0:00:00

Research: Compound Lumbrokinase Isozymes Decrease Hepatitis B Antigens and Protect Hepatic Function
ZHOU Yuan,MOU Li-Xian,FAN Shi-Chao,WANG Xiu-Mei,CAO Xiao,WANG Xue-Qing,ZHANG Feng-Xue,ZHAO Jing,WEI Yan and HE Rong-Qiao.Research: Compound Lumbrokinase Isozymes Decrease Hepatitis B Antigens and Protect Hepatic Function[J].Progress In Biochemistry and Biophysics,2022,49(1):202-218.
Authors:ZHOU Yuan  MOU Li-Xian  FAN Shi-Chao  WANG Xiu-Mei  CAO Xiao  WANG Xue-Qing  ZHANG Feng-Xue  ZHAO Jing  WEI Yan and HE Rong-Qiao
Institution:2) Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China,1) Basic College of Medicine, Southwest Medical University, Luzhou 646000, China,2) Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China,2) Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China,1) Basic College of Medicine, Southwest Medical University, Luzhou 646000, China,3) Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Science, Peking University, Beijing 100191, China,4) School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510099, China,2) Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China,2) Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China,1) Basic College of Medicine, Southwest Medical University, Luzhou 646000, China;2) Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
Abstract:Objective Lumbrokinase isozymes(LKIs),which were isolated from earthworm called Dilong in traditional Chinese medicine(TCM),have been used as the active ingredient of the enteric-coated capsule to treat clotting disease approximately 30 years.Recently,the study of LKIs on other critical diseases received much attention.Methods To demonstrate the efficacy of LKIs on hepatitis B proteins,we incubated surface antigen(HBs Ag),core antigen(HBc Ag)and e antigen(HBe Ag)with LKIs at different concentrations for different time intervals,and then estimated their cleavage sites.Hep G2.2.15 cells were incubated with LKIs and their HBs Ag,Hbe Ag were determined by ELISA and Western blotting.HBV-transgenic mice(Balb/c)were gavaged with LKIs for30 days.HBs Ag and HBe Ag in serum were detected by ELISA and Western blotting,and HBc Ag in hepatic tissues were immunohistochemically stained.Hematoxylin-eosin(HE)staining was used to exhibit liver endolysis of LKI-treated HBV-transgenic mice.Serum glutamic-oxaloacetic transaminase(GOT)and glutamic-pyruvic transaminase(GPT)were semi-quantitatively detected with ELISA.After intraperitoneal injection of LKIs into Sprague Dawley rats,LKIs in serum and liver tissue were assayed.Longyan sheldrakes(LYS)were gavaged with LKIs for 30 days,and their serum HBV DNA were assayed by PCR.Results We observed that the capsule ingredient is a compound drug containing 6 LKIs.By incubating with the HBV proteins,LKIs were probably estimated to degrade HBs Ag at K141/P142 and R160/F161,HBc Ag at R142/E143,and HBe Ag at R122/E123.LKIs significantly inhibited HBs Ag and HBe Ag secretion from Hep G2.2.15 cells.Levels of HBs Ag and HBe Ag in serum and those of HBc Ag in hepatic tissues decreased in HBV-transgenic mice gavaged with LKIs,suggesting a suppression of viral assembly.Levels of GOT and GPT and the number of endolysis in liver exhibited by HE staining were decreased in the LKI-treated HBV-transgenic mice,demonstrating LKIs’protecting mice hepatic cells.The activity of LKIs could be detected in serum and hepatic tissues of Sprague Dawley rats after being intraperitoneally injected with LKIs.After gavaged with LKIs,the ducks showed a decrease in their serum HBV DNA levels.Conclusion The current work indicates that LKIs degrade HBs,HBc and HBe proteins and may interfere with the virion assembly and release,leading to decrease in the virus transmission between hepatocytes,and to hepatic protection.
Keywords:HBeAg  HBcAg  HBsAg  lumbrokinase  hepatitis B virus  isozyme
本文献已被 维普 等数据库收录!
点击此处可从《生物化学与生物物理进展》浏览原始摘要信息
点击此处可从《生物化学与生物物理进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号